Findings

What do systematic reviews say?

5 questions · 5 findings · 4 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

Tricyclic antidepressants vs placebo

Withdrawals due to adverse events · adults with panic disorder

Tricyclic antidepressants probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 1.97 [1.33, 2.91]
10 studies · 1641 participants
Moderate

Tricyclic antidepressants vs placebo

Withdrawals due to adverse events · somatoform disorders in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tricyclic antidepressants vs another medication

Adverse effects (drop‐outs due to adverse effects4) · somatoform disorders in adults

Tricyclic antidepressants showed no clear difference in adverse effects (drop‐outs due to adverse effects4) compared with another medication (low certainty).

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
RR 2.37 [0.39, 14.28]
8 studies · 556 participants
Low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.05 [0.67, 1.64]
1 study · 14 participants
Very low

S‐adenosyl methionine as monotherapy vs tricyclic antidepressants (TCAs)

Acceptability. Participants experiencing troublesome adverse effects of any nature · depression in adults

S‐adenosyl methionine as monotherapy may leads to lower acceptability. Participants experiencing troublesome adverse effects… compared with tricyclic antidepressant agent (low certainty).

1 finding from 1 review

S‐adenosyl methionine (SAMe) for depression in adults 2016 · Cochrane Headline outcomes only
RR 0.68 [0.52, 0.88]
3 studies · 604 participants
Low